Belite Bio

Belite Bio Clinical stage novel oral treatment for Stargardt disease and Dry AMD.

🗓️NEWS: Belite Bio will participate in the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong this ...
02/01/2026

🗓️NEWS: Belite Bio will participate in the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong this February.

The company is set to showcase Phase 3 DRAGON study results for Tinlarebant in Stargardt disease, with oral presentations, a sponsored symposium, and an exhibition presence at one of the world’s leading ophthalmology conferences.

Read more: https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-participation-41st-asia-pacific-academy

We are grateful to our existing and new investors for their support of Belite Bio’s recently announced $350M public offe...
12/03/2025

We are grateful to our existing and new investors for their support of Belite Bio’s recently announced $350M public offering. This important step further strengthens our organization as we prepare for potential commercialization, advance our pipeline, and continue building the infrastructure needed to support our long-term growth.

We remain focused on addressing the significant unmet need in Stargardt disease and geographic atrophy and advancing programs with the potential to meaningfully improve the lives of those affected by degenerative retinal diseases. We look forward to continued progress as we move our mission forward.

Read more: https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-pricing-3500-million-underwritten-public

🔴 Today, Belite Bio shared positive topline results from the pivotal Phase 3 DRAGON trial evaluating Tinlarebant in adol...
12/01/2025

🔴 Today, Belite Bio shared positive topline results from the pivotal Phase 3 DRAGON trial evaluating Tinlarebant in adolescents with Stargardt disease, reflecting meaningful progress in the development of a potential treatment for this condition.

Highlights include:

- 36% reduction in lesion growth vs placebo (p=0.0033)
- First therapeutic candidate to demonstrate efficacy in a global Phase 3 trial in Stargardt disease
- Favorable safety and tolerability profile over 24 months

We extend our deepest gratitude to the patients, families, caregivers, and investigators whose participation and commitment made this milestone possible.

Join our conference call to learn more: https://events.q4inc.com/attendee/851809284

Address

San Diego, CA
92121

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Belite Bio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category